Noxilizer Management Team
- Lawrence Bruder, President & Chief Executive Officer
- Mary Dadone, Ph.D., Vice President, Regulatory Affairs & Quality Assurance
- Ryuichi Iwasaki, Representative Director and General Manager, Japan
- Maura O. Kahn, Vice President, Business Development and Marketing
- David Opie, Ph.D., Senior Vice President, Research and Development
Lawrence Bruder, President & CEO, brings over 25 years of leadership and operational experience in large and small life science companies, including Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Most of his experience prior to Guava was at Becton Dickinson, where he held a number of significant positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high-level business development transactional activity; all of these being a critical part of Noxilizer’s needs. Mr. Bruder holds a B.S. from Rochester Institute of Technology and Master of Management in Marketing & Economics from the Kellogg Graduate School at Northwestern University.
Mary Dadone, Ph.D., Vice President, Regulatory Affairs and Quality Assurance, has nearly 30 years of global medical device regulatory and quality experience with a proven track record in bringing new products to market and building certified quality systems for organizations. She has worked both in-company and as a consultant to a wide range of medical device companies -- innovative start-ups to well-established Fortune 500 corporations. Her expertise encompasses not only regulatory affairs and quality assurance but also biostatistics, technical training, and program management. Dr. Dadone holds a PhD in biological sciences from the University of New Mexico. Additionally, she was a post-doctoral fellow and a research faculty member at the University of Utah School of Medicine.
Ryuichi Iwasaki, Representative Director and General Manager, Japan, Ryuichi Iwasaki, General Manager, Noxilizer Japan K.K., is a 30 year engineering professional recognized for his systems engineering, product development and leadership abilities. He has held leadership positions at several notable Japanese companies including Babcock-Hitachi and Noritsu Koki. His software development and system engineering contributions led to the creation of Noritsu Koki’s best-selling digital photofinishing system, an instant blockbuster. As General Manager at Noritsu Koki, he also organized a collaborative project with Eastman Kodak Company in U.S. to co-develop and commercialize the first photofinishing system. Most recently, he served as a Founder and CEO of SAIAN, which became Noxilizer Japan KK in March 2013, following acquisition by Noxilizer, Inc. Mr. Iwaskai has been recognized for his engineering expertise and leadership by the JSME (The Japan Society of Mechanical Engineers) as an award recipient. Mr. Iwasaki holds a Bachelor of Engineering and a Master of Engineering from the University of Osaka Prefecture. He is based in Wakayama, Japan.
Maura O. Kahn, Vice President, Business Development and Marketing, has 20 years of health care experience. Most recently, Maura was Senior Director of Marketing at MedImmune, responsible for developing and executing the marketing strategy and plan for Synagis. This franchise represents over 80% of total revenue for the company. Maura spent nine years at Eli Lilly in US Diabetes Marketing, Sales Management, Business Development and Global New Product Planning. She was a member of the US Humalog launch team, led the US launch of the Humulin/Humalog Pen and initiated the first ever direct-to-consumer campaign at Lilly. She was a member of the deal teams in Lilly’s successful negotiations with Takeda for Actos and Amylin for Byetta. She began her career at Targeted Communications and The RTC Group. Her clients included political candidates, trade associations and Fortune 500 companies. Ms. Kahn received her B.A. from Saint Mary’s College in Indiana and her MBA from the Kelley School of Business at Indiana University.
David Opie, Ph.D., Senior Vice President, Research and Development, has extensive medical device experience with both start-up companies and industry leaders, including Johnson & Johnson and Cook Medical. He has develop a thorough knowledge of Good Laboratory Practices, Good Manufacturing Practices, and design control procedures. At Noxilizer he leads the technology development and sterilization science initiatives. In addition to membership in several industry organizations, he participates in AAMI standards committees related to sterilization and decontamination. Dr. Opie holds a Ph.D. and an M.S. in physics from the College of William and Mary in Virginia, and a B.A. in Physics from the University of Delaware.